Literature DB >> 17509176

The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime.

A McMillan1, H Young.   

Abstract

An audit of the efficacy treatment of pharyngeal gonorrhoea with a single oral dose of 400 mg of cefixime was undertaken; 83% of patients also received a single oral dose of azithromycin to treat possible concurrent anogenital chlamydial infection. Of the 54 patients studied, only one of 45 patients who attended for at least one test of cure had a positive culture seven days after treatment; the possibility of reinfection could not have been excluded. Two tests of cure were obtained from 18 patients. Cefixime, therefore, seems to be effective in the treatment of pharyngeal gonorrhoea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509176     DOI: 10.1258/095646207780658971

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  5 in total

1.  Chitosan-based electrospun nanofibrous mats, hydrogels and cast films: novel anti-bacterial wound dressing matrices.

Authors:  Sohail Shahzad; Muhammad Yar; Saadat Anwar Siddiqi; Nasir Mahmood; Abdul Rauf; Zafar-ul-Ahsan Qureshi; Muhammad Sabieh Anwar; Shahida Afzaal
Journal:  J Mater Sci Mater Med       Date:  2015-02-26       Impact factor: 3.896

2.  Management of Gonorrhea in Adolescents and Adults in the United States.

Authors:  Sarah Kidd; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

3.  Formulation development, evaluation and comparative study of effects of super disintegrants in cefixime oral disintegrating tablets.

Authors:  Ks Remya; P Beena; Pv Bijesh; A Sheeba
Journal:  J Young Pharm       Date:  2010-07

4.  A conventional HPLC-MS method for the simultaneous determination of ofloxacin and cefixime in plasma: Development and validation.

Authors:  Mahesh V Attimarad; Ahmed O Alnajjar
Journal:  J Basic Clin Pharm       Date:  2013-03

5.  Trends in Neisseria gonorrhoeae Antimicrobial Resistance over a Ten-Year Surveillance Period, Johannesburg, South Africa, 2008⁻2017.

Authors:  Ranmini Kularatne; Venessa Maseko; Lindy Gumede; Tendesayi Kufa
Journal:  Antibiotics (Basel)       Date:  2018-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.